---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-045049"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2025-10-15T23:59:59+00:00"
generated_at: "2026-05-17T03:46:34.642677+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance

## Summary
- GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).
- Medical Devices up 14.8% reported, led by Diabetes Care CGM sales of $2.0B (+20.5% reported, +17.2% organic).
- FY2025 organic sales guidance reaffirmed at 7.5-8.0% ex-COVID; adjusted EPS narrowed to $5.12-$5.18 (midpoint double-digit growth).
- Adjusted operating margin improved 40bps to 23.0% of sales.

## SEC filing metadata
- accession: 0001628280-25-045049
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2025-10-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828025045049/0001628280-25-045049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828025045049/abt-20251015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-045049
- JSON: https://secwatch.observer/filing/0001628280-25-045049.json
- Plain text: https://secwatch.observer/filing/0001628280-25-045049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.